Literature DB >> 15785108

Complement component c5a is integral to the febrile response of mice to lipopolysaccharide.

S Li1, S A Boackle, V M Holers, J D Lambris, C M Blatteis.   

Abstract

OBJECTIVES: The complement system is critical to the febrile response of mice to intraperitoneally administered lipopolysaccharide (LPS). We previously identified C3 and C5 as two components potentially involved in this response. This study was designed to examine whether the complement system is also pivotal in the response of mice to intravenously or intracerebroventricularly injected LPS, to distinguish between C3 and C5 and their cognate derivatives as the essential mediator(s), and to determine whether the failure of complement-deficient mice to develop a fever could be due to their possible inability to secrete pyrogenic cytokines.
METHODS: Wild-type (WT; C57BL/6J) mice, hypocomplemented or not by intravenously injected cobra venom factor (10 U/mouse), and C3-, CR3- and C5-sufficient and -deficient mice were intravenously challenged with LPS (0.25 mug/mouse); WT and C3-/- mice pretreated with a C5a receptor antagonist (C5aRa) were similarly challenged. In addition, the serum levels of interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha and IL-6 were compared in LPS-treated C5+/+ and C5-/- mice.
RESULTS: LPS induced a 1 degrees C rise in core temperature in all the mice, except C5-/- mice and those pretreated with C5aRa. C5+/+ and C5-/- mice challenged intracerebroventricularly with LPS exhibited identical febrile responses. LPS induced similar increases in the serum levels of IL-1beta, TNFalpha and IL-6 in C5+/+ and C5-/- mice.
CONCLUSIONS: C5a is crucial for the development of febrile responses to LPS in mice; its site of action is peripheral, not central. The possibility that an inability to produce cytokines could account for the failure of C5-/- mice to develop a fever is not supported.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15785108     DOI: 10.1159/000083578

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  7 in total

1.  Early life activation of toll-like receptor 4 reprograms neural anti-inflammatory pathways.

Authors:  Abdeslam Mouihate; Michael A Galic; Shaun L Ellis; Sarah J Spencer; Shigeki Tsutsui; Quentin J Pittman
Journal:  J Neurosci       Date:  2010-06-09       Impact factor: 6.167

Review 2.  Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis.

Authors:  Markus Bosmann; Peter A Ward
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

3.  Polysaccharides from Arnebia euchroma Ameliorated Endotoxic Fever and Acute Lung Injury in Rats Through Inhibiting Complement System.

Authors:  Ying-Ye Ou; Yun Jiang; Hong Li; Yun-Yi Zhang; Yan Lu; Dao-Feng Chen
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

4.  Acute lung injury induced by lipopolysaccharide is independent of complement activation.

Authors:  Daniel Rittirsch; Michael A Flierl; Danielle E Day; Brian A Nadeau; Stephanie R McGuire; Laszlo M Hoesel; Kyros Ipaktchi; Firas S Zetoune; J Vidya Sarma; Lin Leng; Markus S Huber-Lang; Thomas A Neff; Richard Bucala; Peter A Ward
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

5.  Circulating and broncho-alveolar interleukin-6 in relation to body temperature in an experimental model of bovine Chlamydia psittaci infection.

Authors:  Annette Prohl; Carola H Ostermann; Christoph D Rummel; Joachim Roth; Petra Reinhold
Journal:  PLoS One       Date:  2017-12-27       Impact factor: 3.240

6.  Sepsis-associated delirium: the pro and con of C5a blockade.

Authors:  Djillali Annane
Journal:  Crit Care       Date:  2009-04-22       Impact factor: 9.097

7.  PKR deficiency alters E. coli-induced sickness behaviors but does not exacerbate neuroimmune responses or bacterial load.

Authors:  David Chun-Hei Poon; Yuen-Shan Ho; Ran You; Hei-Long Tse; Kin Chiu; Raymond Chuen-Chung Chang
Journal:  J Neuroinflammation       Date:  2015-11-19       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.